Literature DB >> 17035329

Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

James H McLinden1, Thomas M Kaufman, Jinhua Xiang, Qing Chang, Donna Klinzman, Alfred M Engel, Georg Hess, Urban Schmidt, Michael Houghton, Jack T Stapleton.   

Abstract

GB virus type C (GBV-C) is a human flavivirus that may cause persistent infection, although most infected individuals clear viremia and develop antibodies to the envelope glycoprotein E2. To study GBV-C E2 antigenicity and cell binding, murine anti-E2 monoclonal antibodies (MAbs) were evaluated to topologically map immunogenic sites on GBV-C E2 and for the ability to detect or block recombinant E2 binding to various cell lines. Five competition groups of MAbs were identified. Groups I and II did not compete with each other. Group III competed with both groups I and II. Group IV did not compete with group I, II, or III. One MAb competed with all of the other MAbs, suggesting that the epitopes bound by these MAbs are intimately related. Individually, none of the MAbs competed extensively with polyclonal human convalescent antibody (PcAb); however, combinations of all five MAb groups completely blocked PcAb binding to E2, suggesting that the epitopes bound by these MAbs form a single, immunodominant antigenic site. Only group I and III MAbs detected purified recombinant E2 bound to cells in binding assays. In contrast, group II MAbs neutralized the binding of E2 to cells. Both PcAb and MAbs were conformation dependent, with the exception of one group II MAb (M6). M6 bound to a five-amino-acid sequence on E2 if the peptide included four C-terminal or eight N-terminal residues, suggesting that the GBV-C E2 protein contains a single immunodominant antigenic site which includes a complex epitope that is involved in specific cellular binding.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035329      PMCID: PMC1676310          DOI: 10.1128/JVI.01206-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Interaction of synthetic peptides corresponding to hepatitis G virus (HGV/GBV-C) E2 structural protein with phospholipid vesicles.

Authors:  Cristina Larios; Bart Christiaens; M José Gómara; M Asunción Alsina; Isabel Haro
Journal:  FEBS J       Date:  2005-05       Impact factor: 5.542

2.  In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus.

Authors:  M Fogeda; S Navas; J Martín; M Casqueiro; E Rodríguez; C Arocena; V Carreño
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Evaluation of RNA and E2 antibodies in prospectively followed recipients of hepatitis G virus-infected blood.

Authors:  S Sauleda; J I Esteban; J M Hernandez; H Reesink; D Castella; J Quer; G Hess; R Esteban; J Guardia
Journal:  Transfusion       Date:  1999-06       Impact factor: 3.157

4.  Effect of early and late GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis.

Authors:  W Zhang; K Chaloner; H L Tillmann; C F Williams; J T Stapleton
Journal:  HIV Med       Date:  2006-04       Impact factor: 3.180

5.  Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection.

Authors:  H L Tillmann; S Heringlake; C Trautwein; D Meissner; B Nashan; H J Schlitt; J Kratochvil; J Hunt; X Qiu; S C Lou; R Pichlmayr; M P Manns
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

6.  Antienvelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model.

Authors:  H M Hassoba; M G Pessoa; N A Terrault; N J Lewis; M Hayden; J C Hunt; X Qiu; S C Lou; T L Wright
Journal:  J Med Virol       Date:  1998-11       Impact factor: 2.327

7.  Evolution of hepatitis G virus infection and antibody response to envelope protein in patients with transfusion-associated non-A, non-B hepatitis.

Authors:  E Tanaka; K Kiyosawa; K Shimoda; K Hino; M Tacke; S Schmolke; A M Engel; G Hess
Journal:  J Viral Hepat       Date:  1998-05       Impact factor: 3.728

8.  Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties.

Authors:  F Habersetzer; A Fournillier; J Dubuisson; D Rosa; S Abrignani; C Wychowski; I Nakano; C Trépo; C Desgranges; G Inchauspé
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

Review 9.  GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals.

Authors:  Philip M Polgreen; Jinhua Xiang; Qing Chang; Jack T Stapleton
Journal:  Microbes Infect       Date:  2003-11       Impact factor: 2.700

Review 10.  GB virus type C/Hepatitis G virus.

Authors:  Jack T Stapleton
Journal:  Semin Liver Dis       Date:  2003-05       Impact factor: 6.115

View more
  15 in total

1.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

2.  GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.

Authors:  Emma L Mohr; Jinhua Xiang; James H McLinden; Thomas M Kaufman; Qing Chang; David C Montefiori; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

3.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

4.  Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard.

Authors:  Jingyang Zhang; Kathryn Chaloner; James H McLinden; Jack T Stapleton
Journal:  Stat Med       Date:  2013-04-17       Impact factor: 2.373

Review 5.  GB virus type C interactions with HIV: the role of envelope glycoproteins.

Authors:  Emma L Mohr; Jack T Stapleton
Journal:  J Viral Hepat       Date:  2009-09-15       Impact factor: 3.728

6.  Human Pegivirus (HPgV; formerly known as GBV-C) inhibits IL-12 dependent natural killer cell function.

Authors:  Ernest T Chivero; Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Jack T Stapleton
Journal:  Virology       Date:  2015-08-01       Impact factor: 3.616

7.  The natural history of non-human GB virus C in captive chimpanzees.

Authors:  Emma L Mohr; Krishna K Murthy; James H McLinden; Jinhua Xiang; Jack T Stapleton
Journal:  J Gen Virol       Date:  2010-09-22       Impact factor: 3.891

Review 8.  The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae.

Authors:  Jack T Stapleton; Steven Foung; A Scott Muerhoff; Jens Bukh; Peter Simmonds
Journal:  J Gen Virol       Date:  2010-11-17       Impact factor: 3.891

9.  GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1.

Authors:  Chenliang Wang; Christine L Timmons; Qiujia Shao; Ballington L Kinlock; Tiffany M Turner; Aikichi Iwamoto; Hui Zhang; Huanliang Liu; Bindong Liu
Journal:  Oncotarget       Date:  2015-12-22

10.  Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material.

Authors:  Yakov Vitrenko; Iryna Kostenko; Kateryna Kulebyakina; Khrystyna Sorochynska
Journal:  Virol J       Date:  2017-08-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.